| Trial | control | p<0.05 | harm | NS |
|---|
| Bailey (MB102014), 2010 | dapagliflozin vs placebo (add on MET) | | | |
| Bolinder, 2012 | dapagliflozin vs placebo (add on MET) | | | |
| Ferrannini (MB102013), 2010 | dapagliflozin vs placebo | | | |
| Wilding (MB102009), 2009 | dapagliflozin vs placebo (add on insulin) | | | |
| Komoroski (MB102007), 2009 | dapagliflozin vs placebo | | | |
| List (MB102008), 2009 | dapagliflozin vs placebo | | | |
| KOhan | dapagliflozin vs placebo | | | |
| Wilding, 2012 | dapagliflozin vs placebo (add on insulin) | | | |
| Nauck, 2011 | dapagliflozin vs dlipizide add on metformin | | | |
| Kohan | dapagliflozin vs placebo | | | |
| Kohan | dapagliflozin + merformin vs dapagliflozin | | | |
| Strojek, 2011 | dapagliflozin + Glimepiride vs glimepiride | | | |
| Rosenstock, 2012 | dapagliflozin vs placebo (add on TZD) | | | |
| MB102034, 2016 | dapagliflozin + merformin vs metformin or dapa | | | |
| Kohan | dapagliflozin vs placebo | | | |
| MB102035 | dapagliflozin vs placebo (on top standard treatment) | | | |
| MB102061 | dapagliflozin vs placebo add on DPP-4 | | | |
| Cefalu, 2015 | dapagliflozin vs placebo (on top standard treatment) | | | |
| Leiter, 2016 | dapagliflozin vs placebo (on top standard treatment) | | | |
| MB102073 | dapagliflozin vs placebo (on top standard treatment) | | | |
| Weber | dapagliflozin vs placebo (on top standard treatment) | | | |
| Schumm-Draeger , 2015 | dapagliflozin vs placebo (add on MET) | | | |
| T1 vs T0 | | | |
| T1 vs T0 | | | |
| T1 vs T0 | | | |
| T1 vs T0 | | | |
| T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Bailey (MB102014), 2010 | dapagliflozin (2¡¤5 mg, n=137; 5 mg, n=137; or 10 mg, n=135) (n=-9) vs. placebo (n=-9) | adults with type 2 diabetes who were receiving daily metformin (¡Ý1500 mg per day) and had inadequate glycaemic control | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: HbA1c FU duration: 24 weeks dose ranging |
| Bolinder, 2012 | dapagliflozin (n=-9) vs. placebo or Sitagliptin (on top MET) (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Ferrannini (MB102013), 2010 | a morning dose of 5 or 10 mg/day dapagliflozin (n=-9) vs. placebo (n=-9) | treatment-naive patients with type 2 diabetes | double-blind Sample size: -9/-9 Primary endpoint: change from baseline in A1C FU duration: 24 weeks |
| Wilding (MB102009), 2009 | 10 mg dapagliflozin, or 20 mg dapagliflozin, plus OAD(s) and 50% of their daily insulin dose (n=-9) vs. placebo (n=-9) | patients with type 2 diabetes that is poorly controlled with high insulin doses plus oral antidiabetic agents | double-blind Sample size: -9/-9 Primary endpoint: change from baseline in A1C FU duration: 12 weeks |
| Komoroski (MB102007), 2009 | daily oral doses of 5-, 25-, or 100-mg doses of dapagliflozin (n=-9) vs. placebo (n=-9) | patients with type 2 diabetes mellitus | Sample size: -9/-9 Primary endpoint: FU duration: 14 days |
| List (MB102008), 2009 | one of five dapagliflozin doses (n=-9) vs. placebo (n=-9) 7 arms trial: five dapagliflozin doses, metformin XR, or placebo | type 2 diabetic patients | Sample size: -9/-9 Primary endpoint: mean change from baseline in A1C FU duration: 12 weeks |
| KOhan | Dapagliflozin monotherapy (n=-9) vs. placebo (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Wilding, 2012 | Dapagliflozin (n=-9) vs. placebo on top of insulin (n=-9) | Type 2 Diabetes With Inadequate Glycaemic Control on Insulin | Sample size: -9/-9 Primary endpoint: FU duration: |
| Nauck, 2011 | Dapagliflozin in Combination With Metformin (n=-9) vs. Sulphonylurea in Combination With Metformin (n=-9) | Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone | Sample size: -9/-9 Primary endpoint: FU duration: |
| Kohan | Dapagliflozin (n=-9) vs. placebo (n=-9) | Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Contro | Sample size: -9/-9 Primary endpoint: FU duration: |
| Kohan | Dapagliflozin in Combination With Metformin (n=-9) vs. Dapagliflozin Monotherapy (n=-9) | Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control | Sample size: -9/-9 Primary endpoint: FU duration: |
| Strojek, 2011 | Dapagliflozin in Comb.With Glimepiride (n=-9) vs. glimepiride alone (n=-9) | Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone | Sample size: -9/-9 Primary endpoint: FU duration: |
| Rosenstock, 2012 | Dapagliflozin in Combination With Thiazolidinedione (n=-9) vs. Thiazolidinedione (n=-9) | Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone | Sample size: -9/-9 Primary endpoint: FU duration: |
| MB102034, 2016 | Dapagliflozin 10 mg in Combination With Metformin (n=-9) vs. Dapagliflozin 10 mg Monotherapy or Metformin Monotherapy (n=-9) | Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control | Sample size: -9/-9 Primary endpoint: FU duration: |
| Kohan | Dapagliflozin as Monotherapy (n=-9) vs. placebo (n=-9) | Japanese Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | Sample size: -9/-9 Primary endpoint: FU duration: |
| MB102035 | Dapagliflozin
Tablets, Oral, 10 mg, once daily, 12 weeks (n=-9) vs. placebo (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| MB102061 | Dapagliflozin
10 mg tablet, oral, once daily, 48 weeks (n=-9) vs. placebo (n=-9) | Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a DPP-4 Inhibitor Sitagliptin+/-Metformin | Sample size: -9/-9 Primary endpoint: FU duration: |
| Cefalu, 2015 | Dapagliflozin
10 mg tablet, oral, once daily, 24- week (n=-9) vs. placebo (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Leiter, 2016 | Dapagliflozin
10 mg tablet, oral, once daily, 24- week treatment (n=-9) vs. placebo (n=-9) | Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care | Sample size: -9/-9 Primary endpoint: FU duration: |
| MB102073 | Dapagliflozin
Tablets, Oral, 10 mg, once daily, up to 12 weeks (n=-9) vs. placebo (n=-9) | patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme (ACE) inhibitor or an Angiotensin Receptor Blocker (ARB). | Sample size: -9/-9 Primary endpoint: FU duration: |
| Weber | Dapagliflozin
Tablets, Oral, 10 mg, once daily, Up to 12 weeks (n=-9) vs. placebo (n=-9) | Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication | Sample size: -9/-9 Primary endpoint: FU duration: |
| Schumm-Draeger , 2015 | Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD (n=-9) vs. placebo (n=-9) | Patients With Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy | Sample size: -9/-9 Primary endpoint: FU duration: |
| Rosenstock, 2015 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: 24 w |
| Yang, 2015 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: Change from baseline in HbA1c FU duration: |
| Matthaei, 2015 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Mathieu, 2015 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: , FU duration: 24 w |
| Kaku, 2014 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: 24 w |
